pros and cons of tirzepatide for weight loss Day 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 GIP receptor agonist Avg Loss: ~20% baseline weight (SURMOUNT-1 trial) FDA Status: Approved type 2 diabetes; Fast-tracked for Who should take them? Pros
Pay in 4 interest-free payments of $6.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19



























